Efficacy and Safety of a Novel Reversible Gastric Bypass Stent System for Weight Loss: A Multicentre Real‐World Study
Authors' conclusion
The GBSS was associated with clinically meaningful weight loss as a minimally invasive intervention. Its safety profile is generally controllable; although stent displacement and intolerance occur, they are manageable.
Study context
- Population
- Patients with overweight or obesity who underwent Gastric Bypass Stent System (GBSS) implantation across 239 hospitals in China; mean BMI 34.4 kg/m²
- Participants
- 1,536 patients239 hospitals
- Outcome
- %TBWL, %EWL and weight loss responder rates (proportion achieving > 5% and > 10% loss)
Methodological detailsmulticentre, real-world, registry data
- Multicentre
- Real-world
- Registry data
Main finding
As reported in the abstract
%TBWL, %EWL and weight loss responder rates (>5% and >10% loss) · 3 months post-implantation
Mean %TBWL (SD 5.5)
11.5%
Mean %EWL (SD 30.4)
50.1%
Achieved >5% weight loss
90.2%
Achieved >10% weight loss
60.7%
Observational data: associations, not effects.
Secondary outcomes
Weight loss stability, 4-12 months after implantation
- Weight loss remained relatively stable (MMRM analysis)
Implantation duration
- Median implantation duration
- 3 months
- Intolerance was the most frequently reported reason for device retrieval
Safety
Adverse events
- Stent displacement
- 4.6%
- Gastrointestinal bleeding
- 4.3%
- Haematemesis
- 2.8%
- Melaena
- 1.5%
- Deaths
- 0
- Surgical interventions
- 0
- All reported adverse events (AEs) managed conservatively or endoscopically
Original publication
Efficacy and Safety of a Novel Reversible Gastric Bypass Stent System for Weight Loss: A Multicentre Real‐World Study. Diabetes Obes Metab. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →